Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis

Area of Science:

• Hematology
• Nephrology
• Pharmacology

Background:

• Thrombotic microangiopathies (TMAs) are a group of disorders with similar clinical presentations but diverse underlying causes.
• Carfilzomib, an irreversible proteasome inhibitor, is used to treat relapsed or refractory multiple myeloma.
• Increasing reports link carfilzomib to thrombotic microangiopathy, yet its precise mechanism remains unclear.

Observation:

• This article details a case of carfilzomib-induced TMA in a multiple myeloma patient.
• The patient experienced end-organ damage, particularly renal complications.
• The presentation mimicked other drug-induced TMAs but had unique pathogenic features.

Findings:

• Carfilzomib-induced TMA carries a high risk of mortality and end-organ damage, especially renal failure.
• The pathogenesis of carfilzomib-induced TMA is not fully elucidated.
• Eculizumab, a complement inhibitor, has shown promise in managing TMA and preventing renal disease progression.

Implications:

• Understanding the mechanism of carfilzomib-induced TMA is crucial for timely diagnosis and intervention.
• Early treatment with agents like eculizumab may be vital for improving patient outcomes and preventing irreversible kidney damage.
• This case highlights the importance of recognizing TMA as a potential complication of proteasome inhibitor therapy.